PaxMedica
General Information | |
Business: |
We are an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). Antipurinergic therapies target the excess production of purines in cells, which can offset homeostasis and result in an overproduction of cellular adenosine triphosphate (or ATP), the main energy molecule in all living cells. |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 4 |
Founded: | 2018 |
Contact Information | |
Address | 50 Tice Boulevard, Suite A26, Woodcliff Lake, NJ 07677, US |
Phone Number | (201) 645-4765 |
Web Address | http://www.paxmedica.com |
View Prospectus: | PaxMedica |
Financial Information | |
Market Cap | $59.1mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-2.1 mil (last 12 months) |
IPO Profile | |
Symbol | PXMD |
Exchange | NASDAQ |
Shares (millions): | 2.5 |
Price range | $5.50 - $6.50 |
Est. $ Volume | $15.0 mil |
Manager / Joint Managers | The Benchmark Company/ Brookline Capital Markets (a division of Arcadia Securities) |
CO-Managers | - |
Expected To Trade: | |
Status: | TBA |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |